Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Cytokinetics Inc. (NASDAQ:CYTK) fell $2.82 (27%) to $7.65 on Tuesday after it and partner Amgen Inc. (NASDAQ:AMGN) said
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury